Secukinumab in children with plaque psoriasis: Study unsuitable for benefit assessment

(Institute for Quality and Efficiency in Health Care) Secukinumab in children with plaque psoriasis: study unsuitable for benefit assessmentThe comparator group was not treated appropriately. Firstly, therapy in this group remained unchanged despite non-response, and secondly, it was continued for longer than approved.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news